Biotest on track to achieve climate neutrality
Last year the company reduced its electricity requirements by 40%
Aware of its energy-intensive production and the resulting impact on the environment, plasma proteins and biological drugs provider Biotest has and is continuing to make significant changes at its Dreieich (Germany) site to combat climate change through CO2-neutral production.
For years, the company has been running a certified energy management system to systematically collect data, present it and tap potential for optimisation in an effot to reduce energy consumption and greenhouse gas emissions.
Similarly, Biotest has been operating highly efficient combined heat and power plants, meaning that in addition to generating electricity for its own needs, the waste heat is also used to air-condition buildings throughout the year.
Last year, Biotest replaced an air conditioning system, which reduced their electricity requirements by 40%. The annual electricity savings from this one project equate to the electricity consumption of approximately 50 households.
Additional targeted measures the company has undertaken include replacing light bulbs, installing electric charging stations for cars, optimising the running time of technical equipment and using natural refrigerants for its cold storage facilities.
The company is currently planning to install photovoltaic systems, which convert light into electric power, on its premises.
To make the remaining energy consumption climate-neutral despite all the measures listed, Biotest obtains its electricity (approximately 30 million kWh) from renewable sources.
Any remaining greenhouse gas emissions generated at the site are offset by voluntary investments in non-profit climate protection projects, such as promoting access to clean energy for communities in rural Vietnam by building biogas plants.
The company says it is also supporting the local campaign to convert monostructural forest areas into climate-stable mixed forests in the Dreieich municipal forest.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance